Claims for Patent: 7,579,326

Summary for Patent: 7,579,326

Title:	Gene switch systems employing regulators with decreased dimerization
Abstract:	Disclosed is a novel inducible expression system characterized by undetectable biological effect in the absence of an inducer, but which exhibits efficient inducibility in the presence of an inducer.
Inventor(s):	Abruzzese; Ronald V (The Woodlands, TX), Mehta; Vidya (Houston, TX), Nordstrom; Jeffrey L (College Station, TX), Fewell; Jason (The Woodlands, TX), O\'Malley; Bert (Houston, TX), Tsai; Sophia (Houston, TX)
Assignee:	Genetronics, Inc. (San Diego, CA) Baylor College of Medicine (Houston, TX)
Application Number:	10/400,053
Patent Claims:	1. An inducible expression system comprising: (a) a first expression cassette including a promoter operably linked to a first nucleic acid sequence encoding a regulator protein, wherein the regulator protein comprises: a mutated GAL-4 DNA-binding domain that carries a mutation in a helical domain located in a region from amino acid 54-93 of SEQ ID NO: 10, wherein the mutation in the helical domain decreases dimerization of the regulator protein occurring in the absence of a anti-progestin ligand, a transregulatory domain selected from the group consisting of NFkappaBp65, VP-16, TAF-1, TAF-2, TAU-1, TAU-2, TEF-1 and ORF-10 transregulatory domains, and a ligand-binding domain of a progesterone receptor, wherein the ligand binding domain has a deletion in naturally occurring amino acids in a region encompassing from about 1 to about 60 carboxyl terminal amino acids of the ligand binding domain, said deletion conferring an ability to be activated by an anti-progestin ligand; and (b) a second expression cassette having a second nucleic acid sequence encoding a desired product, operably linked to a promoter comprising a GAL-4 binding site, wherein the regulator protein is activated in the presence of the anti-progestin and the expression of the second nucleic acid sequence is controlled by binding of the activated regulator protein to Gal-4 binding sites in the promoter region of the second expression cassette. 2. The inducible expression system of claim 1, wherein the mutation to the GAL-4 DNA binding domain and the ligand binding domain is selected from the group consisting of deletion, substitution, or addition. 3. The inducible expression system of claim 2 wherein the mutation is a deletion of amino acids 54-74 of SEQ ID NO: 10. 4. The inducible expression system of claim 2 wherein the mutation is a deletion of amino acids 54-64 of SEQ ID NO: 10. 5. The inducible expression system of claim 2 wherein the mutation is a deletion of amino acids 65-74 of SEQ ID NO: 10. 6. The inducible expression system of claim 2 wherein the mutation is a deletion of amino acids 86-93 of SEQ ID NO: 10. 7. The inducible expression system of claim 1 wherein the mutation in the mutated GAL-4 DNA binding domain is a deletion of the amino acids 75-93 of SEQ ID NO: 10. 8. The inducible expression system of claim 7 wherein the mutated GAL-4 DNA binding domain comprises amino acid sequence 2-74 of SEQ ID NO: 10. 9. The inducible expression system of claim 1 wherein the first expression cassette further comprises a tissue-specific promoter. 10. The inducible expression system of claim 9 wherein the tissue-specific promoter is a muscle-specific promoter. 11. The inducible expression system of claim 10 wherein the muscle-specific promoter is an .alpha.-actin promoter. 12. The inducible expression system of claim 1 wherein one or both of the first and the second expression cassette further comprises a 5' untranslated region that includes a synthetic intron. 13. The inducible expression system of claim 12 wherein the 5' untranslated region comprises SEQ ID NO: 8. 14. The inducible expression system of claim 12 wherein the synthetic intron comprises a sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7. 15. The inducible expression system of claim 1 wherein the first and second expression cassettes further comprise a poly (A) signal derived from the poly (A) signal of human growth hormone. 16. The inducible expression system of claim 1 wherein the deletion is in naturally occurring amino acids 873-933 of the hPR, amino acids 891-933 of the hPR, or amino acids 914-933 of the hPR. 17. The inducible expression system of claim 1 wherein the regulator protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 15 and SEQ ID NO: 24. 18. The inducible expression system of claim 1 wherein the anti-progestin is selected from the group consisting of 11.beta.-(4-dimethylaminophenyl)-17.beta.-hydroxy-17.alpha.-propynyl-4,9-- estradiene-3-one (RU38486 or mifepristone); 11.beta.-(4-dimethylaminophenyl)-17.alpha.-hydroxy-17.beta.-(3-hydroxypro- pyl)-13.alpha. methyl-4,9-gonadiene-3-one (ZK98299 or Onapristone); 11.beta.-(4-acetylphenyl)-17.beta.-hydroxy-17.alpha.-(1-propynyl)-4,9-est- radiene-3-one (ZK112993); 11.beta.-(4-dimethylaminophenyl)-17.beta.-hydroxy-17.alpha.-(3-hydroxy-1(- Z)-propenyl-estra-4,9-diene-3-one (ZK98734); (7.beta.,11.beta.,17.beta.)-11-(4-dimethylaminophenyl)-7-methyl-4',5'-dih- ydrospiro [ester-4,9-diene-17,2'(3'H)-furan]-3-one (Org31806); (11.beta.,14.beta.,17.alpha.)-4',5'-dihydro-11-(4-dimethylaminophenyl)-[s- piroestra-4,9-diene-17,2'(3'H)-furan]-3-one (Org31376); 5-.alpha.-pregnane-3,2-dione, Org 33628, and Org 33245. 19. The inducible expression system of claim 1 wherein the GAL-4 binding site comprises SEQ ID NO: 9. 20. The inducible expression system of claim 1 wherein the promoter region of the second expression cassette comprises a sequence selected from the group consisting of SEQ ID NOS: 18, 19, 20, and 21. 21. The inducible expression system of claim 1 wherein the promoter region of the second expression cassette comprises three to six repeating GAL-4 binding sites. 22. The inducible expression system of claim 1 wherein the transregulatory domain is a human transregulatory domain. 23. The inducible expression system of claim 1 wherein the desired product encoded by the second nucleic acid sequence is selected from the group consisting of erythropoeitin, a clotting factor and an interferon. 24. The inducible expression system of claim 23 wherein the clotting factor is a Factor IX. 25. The inducible expression system of claim 23 wherein the interferon is an interferon alpha. 26. The inducible expression system of claim 1 wherein the second expression cassette manifests an uninduced level of basal expression that does not result in a biological effect from a pharmacological dose of the second expression cassette. 27. The inducible expression system of claim 1 wherein the first and second expression cassette are part of a single nucleic acid vector. 28. The inducible expression system of claim 1 wherein the first expression cassette is part of a first nucleic acid vector and the second expression cassette is part of a second nucleic acid vector. 29. A method of regulating expression of a transgene in vivo comprising: introducing the inducible expression system of claim 1 into a tissue in vivo; administering the anti-progestin to activate the regulator protein and induce expression of the nucleic acid sequence encoding the desired product. 30. The method of claim 29 wherein the amino acid sequence of the regulator protein is selected from the group consisting of SEQ ID NOS: 15 and 24. 31. The method of claim 29 wherein the anti-progestin is administered after inflammation associated with administration of the first and second expression cassettes has subsided. 32. A composition comprising: a polymer selected from the group consisting of non-ionic polymers and anionic polymers, and a pharmacological dose of the inducible expression system of claim 1. 33. The composition of claim 32 wherein the anionic polymer is poly-L-glutamate. 34. The composition of claim 32 wherein the non-ionic polymer is selected from a group consisting of PVP, PVA, and poloxamer. 35. The composition of claim 32 wherein the polymer, the first expression cassette, and the second expression cassette are co-lyophilized. 36. A method of inducing the expression of a transgene, the method comprising: (a) introducing the inducible expression system of claim 1 into a cell; and (b) inducing the expression of the transgene by administering an anti-progestin at least 12 days after the introduction of the inducible expression system into the cell. 37. The method of claim 36 wherein the inducible expression system is delivered by injection followed by electroporation. 38. The method of claim 37 wherein the delivery of the inducible expression system is by injection into muscle, followed by electroporation of the muscle. 39. The method in claim 36 wherein the expression of the transgene is induced at least 18 days after the introduction of the inducible expression system into the cell. 40. The method in claim 36 wherein the expression of the transgene is induced at least 20 days after the introduction of the inducible expression system into the cell. 41. The method in claim 36 wherein the expression of the transgene is induced at least 50 days after the introduction of the inducible expression system into the cell. 42. The method in claim 36 wherein the expression of the transgene is induced at least 54 days after the introduction of the inducible expression system into the cell. 43. The method in claim 36 wherein expression of the transgene is induced using a pulsatile program of induction. 44. The method in claim 36 further comprising the step of formulating the first expression cassette and the second expression cassette with a polymer selected from the group consisting of anionic and non-ionic polymers. 45. The method of claim 44 wherein the anionic polymer is poly-L-glutamate. 46. The method of claim 45 wherein the delivery of the inducible expression system is by intra-muscular injection together with electroporation, wherein the electroporation is conducted following the injection. 47. The method of claim 46 wherein the desired product encoded by the second nucleic acid is selected from the group consisting of erythropoeitin, a clotting factor and an interferon. 48. The method of claim 44 wherein the polymer is selected from a group consisting of PVP, PVA, and poloxamer. 49. A inducible expression system comprising: a first expression cassette having a first nucleic acid sequence encoding a fusion protein comprising a GAL-4 DNA binding domain (SEQ ID NO: 10), wherein amino acids 75-93 are deleted; a NFkappaBp65 transregulatory domain, and a ligand-binding domain of a progesterone receptor having a deletion of about 19 naturally occurring amino acids C-terminal amino acids; and a second expression cassette having a second nucleic acid sequence encoding a desired product, operably linked to a promoter comprising Gal-4 binding sites, wherein the fusion protein is activated in the presence of an anti-progestin and the expression of the second nucleic acid sequence is controlled by binding of the activated fusion protein to the Gal-4 binding sites of the second expression cassette. 50. The inducible system of claim 49 wherein one or both of the first and the second expression cassette further comprises a 5' untranslated region that includes a synthetic intron.

Details for Patent 7,579,326

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-09-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-09-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-09-25